Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -12.89 is 22% above its 5-year average of -16.61, near the high end of its 5-year range (-21.90–-12.85).
25.81% above its 12-month average of -17.38.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.99.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:37:25.874Z. Historical observations retain their original dates. Historical series through 2010-11-04.
EARNINGS PER SHARE (EPS)
-12.89
EARNINGS PER SHARE (EPS) AVG TTM
-17.38
EARNINGS PER SHARE (EPS) AVG 3Y
-17.99
EARNINGS PER SHARE (EPS) AVG 5Y
-16.61
EARNINGS PER SHARE (EPS) AVG 10Y
-46.89
EARNINGS PER SHARE (EPS) AVG 15Y
-19.60
EARNINGS PER SHARE (EPS) AVG 20Y
-26.61
CURRENT VS TTM AVG
+25.81%
CURRENT VS 3Y AVG
+28.36%
CURRENT VS 5Y AVG
+22.42%
CURRENT VS 10Y AVG
+72.51%
CURRENT VS 15Y AVG
+34.23%
CURRENT VS 20Y AVG
+51.57%
Madrigal Pharmaceuticals, Inc.
Market Cap
$11.45B
Earnings Per Share (EPS)
-12.89
TTM Avg
-17.38
3Y Avg
-17.99
5Y Avg
-16.61
Market Cap
$11.34B
Earnings Per Share (EPS)
1.16
TTM Avg
0.82
3Y Avg
1.13
5Y Avg
1.19
Market Cap
$10.98B
Earnings Per Share (EPS)
2.93
TTM Avg
1.92
3Y Avg
1.82
5Y Avg
4.51
Market Cap
$10.83B
Earnings Per Share (EPS)
0.39
TTM Avg
2.04
3Y Avg
1.43
5Y Avg
1.69
Market Cap
$10.72B
Earnings Per Share (EPS)
24.38
TTM Avg
20.29
3Y Avg
15.04
5Y Avg
13.87
Market Cap
$12.33B
Earnings Per Share (EPS)
6.14
TTM Avg
5.08
3Y Avg
4.10
5Y Avg
3.91
Market Cap
$10.55B
Earnings Per Share (EPS)
-2.22
TTM Avg
-2.45
3Y Avg
-3.14
5Y Avg
-3.21
Market Cap
$12.46B
Earnings Per Share (EPS)
1.34
TTM Avg
0.42
3Y Avg
-0.09
5Y Avg
0.01
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals, Inc. (MDGL) | $11.45B | -12.89 | -17.38 | -17.99 | -16.61 |
| Bio-Techne Corporation (TECH)vs › | $11.34B | 1.16 | 0.82 | 1.13 | 1.19 |
| DaVita Inc. (DVA)vs › | $11.58B | 11.38 | 10.37 | 8.56 | 8.35 |
| The Cooper Companies, Inc. (COO)vs › | $10.98B | 2.93 | 1.92 | 1.82 | 4.51 |
| BioMarin Pharmaceutical Inc. (BMRN)vs › | $10.83B | 0.39 | 2.04 | 1.43 | 1.69 |
| Universal Health Services, Inc. (UHS)vs › | $10.72B | 24.38 | 20.29 | 15.04 | 13.87 |
| Encompass Health Corporation (EHC)vs › | $12.33B | 6.14 | 5.08 | 4.10 | 3.91 |
| Twist Bioscience Corporation (TWST)vs › | $10.55B | -2.22 | -2.45 | -3.14 | -3.21 |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.46B | 1.34 | 0.42 | -0.09 | 0.01 |
| Penumbra, Inc. (PEN)vs › | $12.48B | 4.07 | 2.47 | 1.81 | 1.14 |
Trailing EPS (TTM)
$-12.89
Forward EPS (Est.)
$-6.02
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -12.85 |
| 2024-12-31 | -21.90 |
| 2023-12-31 | -19.99 |
| 2022-12-31 | -17.23 |
| 2021-12-31 | -14.63 |
| 2020-12-31 | -13.09 |
| 2019-12-31 | -4.73 |
| 2018-12-31 | -2.22 |
| 2017-12-31 | -2.54 |
| 2016-12-31 | -5.07 |
| 2015-12-31 | -401.56 |
| 2014-12-31 | -30.62 |
| 2013-12-31 | -44.48 |
| 2012-12-31 | -36.99 |
| 2011-12-31 | -35.14 |
| 2010-12-31 | -32.49 |
| 2009-12-31 | 81.55 |
| 2008-12-31 | -96.09 |
| 2007-12-31 | -68.45 |
| 2006-12-31 | -90.03 |
| 2005-12-31 | -108.31 |
| 2004-12-31 | -85.96 |
| 2003-12-31 | -44.65 |
| 2002-12-31 | -105.09 |
| 2001-12-31 | -4.55 |
